Skip to main content
Find more clinical trials

Lifestyle Changes To Slow Progression of Early-Stage Alzheimer's Disease

Start: September 4, 2018
End: September 30, 2023
Enrollment: 100

What Is This Study About?

This study will investigate whether changes in multiple lifestyle factors can help to slow down or reverse the progression of early Alzheimer's disease. Participants will be randomly assigned to a comparison group or a group that receives the intervention, which includes meals and supplements, a personalized exercise program, stress management activities, and group support for 20 weeks. The groups will then rotate for another 20 weeks. After each segment, the researchers will measure changes in cognition, gut bacteria, telomere length, levels of inflammation, cholesterol, blood pressure, and weight. Given COVID-19, the program is currently being delivered via videoconferencing.

Do I Qualify To Participate in This Study?

Minimum Age: 45 Years

Maximum Age: 90 Years

Must have:

  • Current diagnosis of mild dementia or mild cognitive impairment due to Alzheimer's disease
  • Montreal Cognitive Assessment score of 18 or higher
  • Willing and able to participate in all aspects of the study
  • Availability of spouse or caregiver to provide information and make sure the study instructions are followed
  • Willing to receive positron emission tomography scans or blood tests to confirm Alzheimer's disease diagnosis, if needed

Must NOT have:

  • Severe dementia
  • Physical disability that interferes with regular exercise
  • Causes of neurodegeneration or dementia other than Alzheimer's (e.g., Parkinson's disease)
  • Significant, ongoing psychiatric or substance abuse problems

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.


Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Who Sponsors This Study?

Lead: Preventive Medicine Research Institute

Collaborator Sponsor

  • University of California, San Francisco
  • Harvard Medical School
  • University of California, San Diego

Source: ID: NCT04606420